Lasa Supergenerics Ltd Share Price Today - Lasa Supergenerics Ltd Stock Price Live NSE/BSE

Lasa Supergenerics Ltd

NSE: LASA BSE: 540702

₹8.93

(0.22%)

Fri, 13 Feb 2026, 10:38 pm

MTF 5xInvest in Lasa Supergenerics Ltd with 5x Leverage Buy with MTF

Market Cap436.88M

PE Ratio0

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Lasa Supergenerics Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
43.69
Net Profit
-21.73
P/B
1.14
Sector P/E
40.30
P/E
0
EV/EBITDA
0
Debt/Equity (Industry)
0.22
Interest Cover (Industry)
10.71
ROCE (Industry)
11.89
RONW (Industry)
11.62
ROE
0
ROCE
0
Debt/Equity
0.20
EPS (TTM)
0.10
Dividend Yield
0
Book Value
11.25
Interest Cover
-4.20

Analysis

all

Pros

Lasa Supergenerics is profitable, therefore cash runway is not a concern.
Lasa Supergenerics is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (28.1%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 1.6x debt.
Lasa Supergenerics's cash and other short term assets cover its long term commitments.

Cons

Unable to evaluate Lasa Supergenerics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Lasa Supergenerics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Lasa Supergenerics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Interest payments on debt are not well covered by earnings (EBIT is 1.9x annual interest expense, ideally 3x coverage).
High level of physical assets or inventory.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	53.65	53.65	53.65	53.65	53.65
FII	0	0	0	0	0
DII	0	0	0	0	0
Public	46.35	46.35	46.35	46.35	46.35
Government	0	0	0	0	0

Technical Analysis

RSI

41.93

MACD

-0.23

50 DMA

9.53

200 DMA

11.27

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	17.72	13.96	11.67	10.20	7.91	6.44	2.68
Fibonacci	13.96	12.52	11.63	10.20	8.76	7.87	6.44
Camarilla	10.42	10.08	9.73	10.20	9.05	8.70	8.36

Pivots Level: Classic

+7.52

17.72

+3.76

13.96

+1.48

11.67

10.20

Pivot Point

LTP: 8.93

-2.28

7.91

-3.76

6.44

-7.52

2.68

Moving Average

SMAEMA

Period

Value

10-EMA
9.00
20-EMA
9.18
30-EMA
9.32
50-EMA
9.55
100-EMA
10.19
200-EMA
12.28

Announcement Date	Purpose	Action	Ex Date
13 Feb 2026	board-meetings	Quarterly Results
14 Nov 2025	board-meetings	Quarterly Results
05 Sept 2025	agm
28 Jan 2025	egm
03 Sept 2024	agm
02 Sept 2023	agm
05 Sept 2022	agm
11 Apr 2022	dividend	₹0.25 Dividend /Share	19 Sept 2022
23 Aug 2021	agm
31 May 2021	dividend	₹0.25 Dividend /Share	17 Sept 2021

Lasa Supergenerics Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Divis Laboratories Ltd

Lasa Supergenerics Ltd About

Lasa Supergenerics is primarily engaged in the business of manufacturing API bulk drugs products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2016

Headquarters

CEO

Omkar P Herlekar

Employees

Contact

Website

http://www.lasalabs.com

cs@lasalabs.com

Phone

91-2145-232101/232202

Location

C-105 MIDC, Mahad, Raigad, Maharashtra, 402301

Year	History
2013	The Companies Act was established.
2016	Lasa Supergenerics Limited was incorporated as a public limited company.
2021	LASA launched new product Oxyclozanide Creating new Capacity as a brown field expansion.

Client Name	Order Side	QTY	Avg Price	Date
AMIT KUMAR JAIN HUF	Sell	224606	10.65	08 Sept 2025
AMIT KUMAR JAIN HUF	Buy	398113	10.57	08 Sept 2025
BNP ENTERPRISES	Sell	284542	17.28	22 May 2025
MANBHUPINDER SINGH ATWAL	Sell	280000	28.38	01 Jan 2024

Lasa Supergenerics Ltd News

Lasa Supergenerics Reports Q3FY26 Loss of Rs 255.47 Lakh

Lasa Supergenerics Limited posted a net loss of Rs 255.47 lakh for Q3FY26, with revenue declining to Rs 219.93 lakh from Rs 3,307.99 lakh in Q3FY25. Operations remain suspended following May 2025 fire incident.

13 Feb 2026

co actions results

LASA Supergenerics Appoints New Executive Director

LASA Supergenerics Limited announces the appointment of Mr. Ganesh Suresh Potdar as Additional Director in Executive capacity and Occupier of all company units, effective January 02, 2026.

02 Jan 2026

stocks

Lasa Supergenerics Appoints New Company Secretary

Lasa Supergenerics Limited announces the appointment of Mrs. Mitti Jain as Company Secretary and Compliance Officer effective December 16, 2025, bringing 10 years of corporate law experience.

15 Dec 2025

stocks

Lasa Supergenerics Director Prathmesh Chalke Resigns

Lasa Supergenerics Limited announces resignation of Whole-time Director Mr. Prathmesh Chalke effective December 31, 2025, citing no material reasons beyond those in resignation letter.

11 Dec 2025

stocks

Lasa Super Generics Reports Rs 2,821.93 Lakh Loss After Factory Fire Halts Operations

Lasa Super Generics Limited reported a net loss of Rs 2,821.93 lakhs for the quarter ended September 30, 2025, primarily due to a fire incident at its main manufacturing facility in May 2025 that destroyed inventories and equipment worth Rs 1,973.62 lakhs. The company has suspended all manufacturing operations across its facilities and is exploring contract manufacturing arrangements or facility leasing options to resume business.

14 Nov 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800